Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and autoimmune diseases, is pleased to announce that the European Patent Office has granted a wide-ranging patent (number 1207899) covering the use of its lead product candidate, rEV131, in the treatment of allergic rhinitis. The patent also covers the use of any functionally equivalent molecule to treat allergic rhinitis.
